Clinical applications and acute hepatotoxicity of intravenous amiodarone

Journal of International Medical Research

Volumn 37, Issue 6, 2009, Pages 1928-1936

  Huang, X ^a   Yang, Yanmin ^a   Zhu, J ^a   Gao, X ^a   Wang, G ^a   Tan, H ^a   Liang, Y ^a   Li, J ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Amiodarone; Arrhythmia; Atrial fibrillation; Hepatotoxicity; Indications; Intravenous injection

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIODARONE; BILIRUBIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHINA; CLINICAL STUDY; CROSS-SECTIONAL STUDY; DRUG INDICATION; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FUNCTION; HEART VENTRICLE ARRHYTHMIA; HOSPITAL; HUMAN; INCIDENCE; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; RECORDING; RETROSPECTIVE STUDY; STANDARDIZATION;

EID: 74949091570     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700631     Document Type: Article

References (22)

1. Goldschlager N, Epstein AE, Naccarelli G, et al: Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000; 160: 1741-1748.
2. Goldschlager N, Epstein AE, Naccarelli GV, et al: A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm 2007; 4: 1250-1259.
3. Jiang WP: Amiodarone guideline for arrhythmia in China. Chin J Cardiol 2004; 32: 1065-1071 [In Chinese].
4. Bagshaw SM, Galbraith PD, Mitchell LB, et al: Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis. Ann Thorac Surg 2006; 82: 1927-1937.
5. Podrid PJ: Amiodarone: reevaluation of an old drug. Ann Intern Med 1995; 122: 689-700.
6. Vassallo P, Trohman RG: Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007; 298: 1312 - 1322.
7. Ratz Bravo AE, Drewe J, Schlienger RG, et al: Hepatotoxicity during rapid intravenous loading with amiodarone: description of three cases and review of the literature. Crit Care Med 2005; 33: 128-134.
8. Lewis JH, Ranard RC, Caruso A, et al: Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989; 9: 679-685.
9. Hyatt RH, Sinha B, Vallon A, et al: Noncardiac side-effects of long-term oral amiodarone in the elderly. Age Ageing 1988; 17: 116-122.
10. Agozzino F, Picca M, Pelosi G: Acute hepatitis complicating intravenous amiodarone treatment. Ital Heart J 2002; 3: 686-688.
11. Chan AL, Hsieh HJ, Hsieh YA, et al: Fatal amiodarone-induced hepatotoxicity: a case report and literature review. Int J Clin Pharmacol Ther 2008; 46: 96-101.
12. Rhodes A, Eastwood JB, Smith SA: Early acute hepatitis with parenteral amiodarone: a toxic effect of the vehicle? Gut 1993; 34: 565-566.
13. Criteria Committee of the New York Heart Association: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th edn (Levin RI, Dolgin M, Fox AC, et al, eds). Boston: Little Brown & Co, 1994.
14. Kum LC, Chan WW, Hui HH, et al: Prevalence of amiodarone-related hepatotoxicity in 720 Chinese patients with or without baseline liver dysfunction. Clin Cardiol 2006; 29: 295-299.
15. Maria VA, Victorino RM: Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26: 664-669.
16. Somberg JC, Bailin SJ, Haffajee CI, et al: Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. Am J Cardiol 2002; 90: 853-859.
17. Anastasiou-Nana MI, Nanas JN, Nanas SN, et al: Effects of amiodarone on refractory ventricular fibrillation in acute myocardial infarction: experimental study. J Am Coll Cardiol 1994; 23: 253-258.
18. Dorian P, Cass D, Schwartz B, et al: Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 2002; 346: 884-890.
19. Pollak PT, Shafer SL: Use of population modeling to define rational monitoring of amiodarone hepatic effects. Clin Pharmacol Ther 2004; 75: 342-351.
20. Llanos L, Moreu R, Peiró AM, et al: Causality assessment of liver injury after chronic oral amiodarone intake. Pharmacoepidemiol Drug Saf 2009; 18: 291-300.
21. Pye M, Northcote RJ, Cobbe SM: Acute hepatitis after parenteral amiodarone administration. Br Heart J 1988; 59: 690-691.
22. Tisdale JE, Follin SL, Ordelova A, et al: Risk factors for the development of specific noncardiovascular adverse effects associated with amiodarone. J Clin Pharmacol 1995; 35: 351-356.